Incorporating historical information to improve phase I clinical trials

Yanhong Zhou, J. Jack Lee, Shunguang Wang, Stuart Bailey, Ying Yuan

Type: Article

Publication Date: 2021-04-01

Citations: 14

DOI: https://doi.org/10.1002/pst.2121

View Publication

Locations

Pharmaceutical Statistics - View
PubMed - View

Similar Works

Action	Title	Year	Authors
+ PDF Chat	Incorporating historical information to improve phase I clinical trial designs	2020	Yanhong Zhou J. Jack Lee Shunguang Wang Stuart Bailey Ying Yuan
+	Incorporating historical information to improve phase I clinical trial designs	2020	Yanhong Zhou J.Jack Lee Shunguang Wang Stuart Bailey Ying Yuan
+	Comparative review of novel model‐assisted designs for phase I clinical trials	2018	Heng Zhou Thomas A. Murray Haitao Pan Ying Yuan
+	Accuracy, Safety, and Reliability of Novel Phase I Trial Designs	2018	Heng Zhou Ying Yuan Lei Nie
+	Borrowing historical information to improve phase I clinical trials using meta-analytic-predictive priors	2022	Xin Chen Jingyi Zhang Qian Jiang Fangrong Yan
+	Data from Accuracy, Safety, and Reliability of Novel Phase I Trial Designs	2023	Heng Zhou Ying Yuan Lei Nie
+	Data from Accuracy, Safety, and Reliability of Novel Phase I Trial Designs	2023	Heng Zhou Ying Yuan Lei Nie
+	Evaluating the effects of design parameters on the performances of phase I trial designs	2019	Angela Y. Zhu Wei‐Ting Hwang Yimei Li
+	Time-to-Event Model-Assisted Designs to Accelerate Phase I Clinical Trials	2018	Ruitao Lin Ying Yuan
+ PDF Chat	Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials	2018	Ying Yuan Ruitao Lin Daniel Li Lei Nie Katherine E. Warren
+	Hi3+3: A Model-Assisted Dose-Finding Design Borrowing Historical Data	2020	Yunshan Duan Sue-Jane Wang Yuan Ji
+	Data from Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials	2023	Ying Yuan Ruitao Lin Daniel Li Lei Nie Katherine E. Warren
+	Data from Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials	2023	Ying Yuan Ruitao Lin Daniel Li Lei Nie Katherine E. Warren
+ PDF Chat	Time-to-event model-assisted designs for dose-finding trials with delayed toxicity	2019	Ruitao Lin Ying Yuan
+	Introduction to Phase I Dose-Finding Clinical Trials	2023	Haitao Pan Ying Yuan
+ PDF Chat	A phase I dose-finding design with incorporation of historical information and adaptive shrinking boundaries	2020	Chen Li Haitao Pan
+ PDF Chat	Enhancing phase I dose-finding trials design through dynamic borrowing information and handling late-onset toxicity	2023	Wen-Yun Yang Ruyue He Yuehan Sun Fangrong Yan Fei Wang
+	Early completion of phase I cancer clinical trials with Bayesian optimal interval design	2021	Masahiro Kojima
+	Multi-stage dose expansion cohort (MSDEC) design with Bayesian stopping rule	2022	Shuqi Wang Ming Tan
+ PDF Chat	Bayesian Optimal Interval Design for Phase I Oncology Clinical Trials	2015	Bryan Fellman Ying Yuan

Works That Cite This (14)

Action	Title	Year	Authors
+ PDF Chat	A comparison of model-free phase I dose escalation designs for dual-agent combination therapies	2024	Helen Barnett M. C. George Donia Skanji Gaëlle Saint‐Hilary Thomas Jaki Pavel Mozgunov
+ PDF Chat	A dose-finding design for phase I clinical trials based on Bayesian stochastic approximation	2022	Jin Xu Dapeng Zhang Rongji Mu
+ PDF Chat	Overview of model-assisted design for phase I dose-finding trials in oncology	2022	Koichi Hashizume Kentaro Takeda Hiroyuki Sato Akihiro Hirakawa Takashi Sozu
+	Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: <scp>iBOIN‐ET</scp>	2022	Yunqi Zhao Rachael Liu Kentaro Takeda
+	BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials	2021	Yanhong Zhou Ruitao Lin Ying-Wei Kuo J. Jack Lee Ying Yuan
+ PDF Chat	A Bayesian optimal interval design for dose optimization with a randomization scheme based on pharmacokinetics outcomes in oncology	2023	Kentaro Takeda Jing Zhu Ran Li Yusuke Yamaguchi
+	A Comparative Study of Bayesian Optimal Interval (BOIN) Design With Interval 3 + 3 (i3 + 3) Design for Phase I Oncology Dose-Finding Trials	2020	Yanhong Zhou Ruobing Li Fangrong Yan J. Jack Lee Ying Yuan
+ PDF Chat	Optimizing dose-schedule regimens with bayesian adaptive designs: opportunities and challenges	2023	Xin Chen Ruyue He Xinyi Chen Liyun Jiang Fei Wang
+	BOIN-ETC: A Bayesian optimal interval design considering efficacy and toxicity to identify the optimal dose combinations	2024	Tomoyuki Kakizume Kentaro Takeda Masataka Taguri Satoshi Morita
+	<scp>AIDE</scp>: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials	2022	Yanhong Zhou Yujie Zhao Greg Cicconetti Yunming Mu Ying Yuan Li Wang Sudhir Penugonda Zeena Salman

Works Cited by This (24)

Action	Title	Year	Authors
+ PDF Chat	Bayesian optimal interval designs for phase I clinical trials	2014	Suyu Liu Ying Yuan
+ PDF Chat	Application of the continual reassessment method to a phase I dose‐finding trial in Japanese patients: East meets West	2011	Satoshi Morita
+	Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials	2009	Guosheng Yin Ying Yuan
+ PDF Chat	Power prior distributions for regression models	2000	Ming‐Hui Chen Joseph G. Ibrahim
+	An approach to meta‐analysis of dose‐finding studies	2011	Sarah Zohar Sandrine Katsahian John O’Quigley
+ PDF Chat	Determining the Effective Sample Size of a Parametric Prior	2007	Satoshi Morita Peter F. Thall Peter Müller
+ PDF Chat	Critical aspects of the Bayesian approach to phase I cancer trials	2008	Beat Neuenschwander Michael Branson Thomas Gsponer
+	Cancer phase I clinical trials: efficient dose escalation with overdose control	1998	James S. Babb André Rogatko Shelemyahu Zacks
+	Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer	1990	John O’Quigley Margaret S. Pepe Lloyd D. Fisher
+ PDF Chat	A modified toxicity probability interval method for dose-finding trials	2010	Yuan Ji Ping Liu Yisheng Li B. Nebiyou Bekele